SHMT1 and osteosarcoma: However, prognostic studies for the other candidate genes require the development of new antibodies (C17orf39, RICH2, RASD1) or testing of available antibodies on osteosarcoma tissues (TOP3A, COPS3, SHMT1, PRPSAP2, PMP22), which is presently underway.